Cytotoxic compounds and conjugates thereof
AssigneeSeagen Inc.
InventorsPhilip MOQUIST, Svetlana DORONINA, Nicole DUNCAN, Gabriele BLAHNIK-FAGAN, Sharsti SANDALL
Life of this patent
Estimating the term…
Abstract
Hydrophilic auristatin compounds are described, including Drug-Linker compounds, Ligand-Drug Conjugate compounds, methods of use, and preparations thereof.
Claims119
A compound of Formula (I):
- or a salt thereof, wherein
- Xb is —NR1R2;
- and Xa is
- or
- Xa and Xb are taken together with the carbon atom to which they are attached to form
- wherein the asterisk denotes the carbon atom of Formula (I) that bears the Xa and Xb groups;
- R1, R2, R3, R4, Ra, Rb, R5, and R10 are each independently H or C1-C4 alkyl;
- X is H, OH, —C(O)NRaRb, —S(O)2Ra, —S(O)—Ra —S(O)2NRaRb, —NHS(O)2Ra, or —NHC(O)Ra;
- R6 is C1-C4 alkyl optionally substituted with OH;
- R7 is H, C1-C4 alkyl optionally substituted with one or two OH moieties, or 5-6 membered heteroaryl;
- E is phenyl or 5-6 membered heteroaryl;
- R8, R9, and R11 are each independently H or OH;
- n is 0, 1, 2, or 3;
- m is 1, 2, 3, or 4;
- and
- q is 0 or 1,
- wherein when X is H, at least two of R7, R8, R9, and R11 comprise an OH moiety.
A compound of Formula (II):
- or a salt thereof, wherein
- R1, R3, and R4 are independently H or C1-C4 alkyl;
- R6 is C1-C4 alkyl optionally substituted with OH;
- R7 is H, C1-C4 alkyl optionally substituted with one or two OH moieties, or 5-6 membered heteroaryl;
- E is phenyl or 5-6 membered heteroaryl;
- R8, R9, and R11 are each independently H or OH;
- n is 0, 1, or 2;
- and
- q is 0 or 1.
A Drug-Linker compound of the following formula:
- Q-D,
- or a salt thereof, wherein
- Q is a Linker Unit selected from the group consisting of:
- (i) Z′-A-RL-,
- (ii) Z′-A-RL-Y—,
- (iii) Z′-A-S*—RL-,
- (iv) Z′-A-S*—RL-Y—,
- (v) Z′-A-B(S*)—RL-,
- (vi) Z′-A-B(S*)—RL-Y—,
- (vii) Z′-A-,
- (viii) Z′-A-S*—W—,
- (ix) Z′-A-B(S*)—W—,
- (x) Z′-A-S*—W-RL-, and
- (xi) Z′-A-B(S*)—W-RL-;
- Z′ is a Stretcher Unit precursor;
- A is a bond or a Connector Unit;
- B is a Parallel Connector Unit;
- S* is a Partitioning Agent;
- RL is a Releasable Linker;
- W is an Amino Acid Unit;
- Y is a Spacer Unit;
- and
- D is a Drug Unit of Formula (I′):
- wherein
- Xb is —NR2—# or —N+R1R5—#, wherein the # denotes the point of attachment to Q, and Xa is
- or
- Xa and Xb are taken together with the carbon atom to which they are attached to form
- wherein the asterisk denotes the carbon atom of Formula (I) that bears the Xa and Xb groups, and the # denotes the point of attachment to Q;
- R1 and R5 are independently C1-C4 alkyl;
- X is H, OH, —C(O)NRaRb, —S(O)2Ra, —S(O)—Ra —S(O)2NRaRb, —NHS(O)2Ra, or —NHC(O)Ra;
- R2, R3, R4, R10, Ra, and Rb are each independently H or C1-C4 alkyl;
- R6 is C1-C4 alkyl optionally substituted with OH;
- R7 is H, C1-C4 alkyl optionally substituted with one or two OH moieties, or 5-6 membered heteroaryl;
- E is phenyl or 5-6 membered heteroaryl;
- R8, R9, and R11 are each independently H or OH;
- n is 0, 1, 2, or 3;
- m is 1, 2, 3, or 4;
- q is 0 or 1;
- and
- wherein when X is H, at least two of R7, R8, R9, and R11 comprise an OH moiety.
A Ligand-Drug Conjugate compound of the formula:
- L-(Q-D)p
- or a pharmaceutically acceptable salt thereof, wherein
- L is a Ligand Unit;
- Q is a Linker Unit selected from the group consisting of:
- (i) Z′-A-RL-,
- (ii) Z′-A-RL-Y—,
- (iii) Z′-A-S*—RL-,
- (iv) Z′-A-S*—RL-Y—,
- (v) Z′-A-B(S*)—RL-,
- (vi) Z′-A-B(S*)—RL-Y—,
- (vii) Z′-A-,
- (viii) Z′-A-S*—W—,
- (ix) Z′-A-B(S*)—W—,
- (x) Z′-A-S*—W-RL-, and
- (xi) Z′-A-B(S*)—W-RL-;
- Z′ is a Stretcher Unit;
- A is a bond or a Connector Unit;
- B is a Parallel Connector Unit;
- S* is a Partitioning Agent;
- RL is a Releasable Linker;
- W is a Amino Acid Unit;
- Y is a Spacer Unit;
- and
- D is a Drug Unit of Formula (I′):
- wherein
- Xb is —NR2—# or —N+R1R5—#, wherein the # denotes the point of attachment to Q, and Xa is
- or
- Xa and Xb are taken together with the carbon atom to which they are attached to form
- wherein the asterisk denotes the carbon atom of Formula (I) that bears the Xa and Xb groups, and the # denotes the point of attachment to Q;
- R1 and R5 are independently C1-C4 alkyl;
- X is H, OH, —C(O)NRaRb, —S(O)2Ra, —S(O)—Ra —S(O)2NRaRb, —NHS(O)2Ra, or —NHC(O)Ra;
- R2, R3, R4, R10, Ra, and Rb are each independently H or C1-C4 alkyl;
- R6 is C1-C4 alkyl optionally substituted with OH;
- R7 is H, C1-C4 alkyl optionally substituted with one or two OH moieties, or 5-6 membered heteroaryl;
- E is phenyl or 5-6 membered heteroaryl;
- R8, R9, and R11 are each independently H or OH;
- n is 0, 1, 2, or 3;
- m is 1, 2, 3, or 4;
- q is 0 or 1;
- p is an integer ranging from 1 to 12;
- and
- wherein when X is H, at least two of R7, R8, R9, and R11 comprise an OH moiety.
A compound, wherein the compound is selected from the group consisting of the compounds listed in Table 1 or a salt thereof.
A Drug-Linker compound, wherein the Drug-Linker compound is selected from the group consisting of the compounds listed in Table 2 or a salt thereof.
A Ligand-Drug Conjugate compound, wherein the Ligand-Drug Conjugate compound is selected from the group consisting of the compounds listed in Table 3, or a salt thereof, and p is an integer ranging from 1 to 12.
A Ligand-Drug Conjugate of the following formula:
- wherein L is an anti-gpNMB antibody,
- and p is an integer from 1 to 14, or from 1 to 8, or is 8.
Dependencies are inferred from the claim text.